Seasonal Affective Disorder: The Evidence-Based Supplement Protocol

← Back to articles

Seasonal affective disorder (SAD) is a recurrent, winter-pattern form of major depression that lifts in spring. The single most important point for any supplement-focused reader is that supplements are not the front-line treatment. Bright light therapy and certain antidepressants have the strongest evidence; supplements are, at best, adjuncts, and the popular ones are weaker than their marketing suggests. The sections below are graded by the actual controlled evidence.

Light Therapy — First-Line (Not a Supplement)

Bright light therapy is the established first-line treatment and the reason this protocol leads with it. In a head-to-head randomized trial of 177 adults with seasonal major depression, light therapy (10,000 lux, 30 minutes each morning) and SAD-tailored cognitive behavioral therapy produced comparable acute remission rates (about 47% each) (Rohan 2015). In nonseasonal depression, light monotherapy beat a sham placebo with a large effect size (Cohen's d 0.80) and outperformed fluoxetine alone (Lam 2016), supporting the biological plausibility of light as an antidepressant. Evidence for using light to prevent a winter episode before it starts is thin — a Cochrane review found only one small eligible trial (Nussbaumer-Streit 2019) — so light is best deployed as treatment once symptoms appear. Any supplement plan for SAD that omits light therapy is incomplete.

Omega-3 (EPA-Predominant) — Limited-to-Moderate Evidence

Omega-3 fatty acids have the best supplement evidence here, though it is borrowed largely from general major depression rather than SAD specifically. A meta-analysis of 13 placebo-controlled trials in major depressive disorder found an overall benefit (standardized mean difference 0.40), with the effect concentrated in EPA-predominant formulations and in patients already taking an antidepressant (Mocking 2016). Dedicated SAD trials are scarce, so treat this as a reasonable adjunct, not a proven SAD therapy. Typical dose: 1–2 g/day of EPA, from a product where EPA exceeds DHA. Cautions: mild GI upset; theoretical bleeding risk at high doses with anticoagulants. See our omega-3 and depression piece.

Saffron — Limited Evidence (Borrowed from MDD)

Saffron (Crocus sativus) has surprisingly good antidepressant data in general MDD: a meta-analysis of five RCTs found a large effect versus placebo and efficacy comparable to standard antidepressants in head-to-head arms (Hausenblas 2013). However, those trials were small, mostly conducted in Iran, and not specific to the seasonal pattern, so the SAD-specific evidence is limited. It is a defensible adjunct for mild-to-moderate seasonal low mood. Typical dose: 30 mg/day of a standardized extract. Cautions: avoid in pregnancy; theoretical additive serotonergic effect with antidepressants. See our saffron piece.

Vitamin D — Weak / Inconsistent Evidence

Despite the intuitive "winter sunlight" story, the evidence that vitamin D treats SAD is weak. A meta-analysis of four trials in clinically diagnosed major depression found a moderate effect (0.58) but flagged few trials and methodological limitations (Vellekkatt 2019), and results are inconsistent in people who are already vitamin-D-replete. The reasonable, low-risk position is to test 25-hydroxyvitamin D and correct a genuine deficiency rather than expect repletion to function as an antidepressant. Typical dose: 1,000–2,000 IU/day for maintenance, higher short-term only to correct documented deficiency. Caution: avoid sustained high doses (hypercalcemia risk). See our vitamin D piece.

Melatonin — Circadian Timing, Not a Mood Drug

One model of SAD involves a delay in circadian phase during winter. Correctly timed low-dose melatonin can shift circadian timing (Lewy 2006), and a small amount in the afternoon/evening has been studied to advance a delayed phase. Melatonin is not an antidepressant and should be thought of as a tool that targets one mechanistic component, ideally with clinician guidance on timing. Typical dose: a low physiological dose (e.g. 0.3–0.5 mg), timing-dependent. Caution: wrong-time dosing can worsen phase problems and cause daytime grogginess. See our melatonin dosing piece.

What Doesn't Work / Overhyped

Skip "winter blues" or "mood support" megaformulas with many sub-clinical-dose ingredients. Do not combine St. John's Wort with an SSRI or other serotonergic medication — the combination risks serotonin syndrome, and St. John's Wort also induces drug-metabolizing enzymes that can reduce levels of many medications (including hormonal contraceptives and anticoagulants). For the same reason, avoid 5-HTP alongside any serotonergic drug. Most importantly, do not substitute supplements for light therapy or prescribed treatment in moderate-to-severe SAD.

How to Run the Protocol

Start with what works: bright light therapy at 10,000 lux for ~30 minutes within an hour of waking, daily through the dark months, is the evidence-based foundation. Get outdoors during daylight when possible — even an overcast sky delivers far more lux than typical indoor lighting. Test and correct a true vitamin D deficiency. Consider EPA-predominant omega-3 (1–2 g EPA/day) as an adjunct, and saffron 30 mg/day for mild mood symptoms. If symptoms are moderate-to-severe or persist despite light therapy, see a clinician: bupropion XL is supported for preventing recurrence in people with a known SAD history (Gartlehner 2019), and SSRIs/SNRIs and CBT are effective treatments. Add only one agent at a time so you can tell what is actually helping, and seek urgent care for any suicidal thoughts.